CTRI/2009/091/000952已完成2 期
A phase 2, 6-week, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of oral OPC-34712 once daily and aripiprazole once daily for treatment of hospitalized adult patients with acute schizophrenia.
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 450
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1.Male or female subjects between 18 and 65 years of age, with a diagnosis of schizophrenia, as defined by DSM-IV-TR criteria
- •2.Subjects who have been recently hospitalized or who would benefit from hospitalization for an acute relapse of schizophrenia
- •3.Subjects experiencing an acute exacerbation of psychotic symptoms
排除标准
- •1.Females who are breast-feeding and/or who have a positive pregnancy test result prior to receiving study drug
- •2.Subjects with a current DSM-IV-TR Axis I diagnosis of:
- •oSchizoaffective disorder
- •oBipolar disorder
- •oDelirium, dementia, amnestic or other cognitive disorder
- •oBorderline, paranoid, histrionic, schizotypal, schizoid or antisocial personality disorder
- •3.Subjects presenting with a first episode of schizophrenia
- •4.Other protocol specific inclusion/exclusion criteria may apply
研究者
相似试验
进行中（未招募）
1 期
A study to test the effect of different doses of BI 1358894 and quetiapine in people with depression.Major Depressive DisorderEUCTR2019-004264-21-DEBoehringer Ingelheim Pharma GmbH & Co. KG431
进行中（未招募）
1 期
A study to test the effect of different doses of BI 1358894 and quetiapine in people with depression.Depressive DisorderMedDRA version: 20.0Level: HLTClassification code 10012401Term: Depressive disordersSystem Organ Class: 100000004873EUCTR2019-004264-21-HUBoehringer Ingelheim RCV GmbH & Co KG431
招募中
2 期
A study to test the effect of different doses of BI 1358894 and quetiapine in people with depression.Major Depressive DisorderJPRN-jRCT2080225310Boehringer Ingelheim431
进行中（未招募）
1 期
A study to test the effect of different doses of BI 1358894 andquetiapine in people with depression.Depressive DisorderMedDRA version: 20.0Level: HLTClassification code 10012401Term: Depressive disordersSystem Organ Class: 100000004873EUCTR2019-004264-21-PLBoehringer Ingelheim RCV GmbH & Co KG431
进行中（未招募）
1 期
A study to test the effect of different doses of BI 1358894 andquetiapine in people with depression.Depressive DisorderMedDRA version: 20.0Level: HLTClassification code 10012401Term: Depressive disordersSystem Organ Class: 100000004873EUCTR2019-004264-21-CZBoehringer Ingelheim Pharma GmbH & Co. KG431